All In Biotech

Drug Trial Radar · NCT06797518

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 21, 2025

Primary completion

Nov 27, 2027

Study completion Nov 27, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. The study aims to provide insights into the treatment's systemic and kidney-specific aspects by quantifying the change in mesangial C3c containing fragments deposition, as an indicator of complement activation, and evaluating a variety of biomarkers related to kidney function, damage, and disease progression, including but not limited to Oxford MEST-C score.

Conditions

  • Glomerulonephritis, IGA
  • Immunoglobulin A Nephropathy

Interventions

  • IptacopanDrug

    LNP023 oral capsule 200 mg b.i.d

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving a reduction of minimum one order of magnitude in complement C3c mesangial deposition.Time frame: BSL, Month 9

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • UCLA Medical Center

    Los Angeles, California · Recruiting

  • Central Florida Kidney Specialists

    Orlando, Florida · Recruiting

  • Georgia Nephrology Research Inst

    Lawrenceville, Georgia · Recruiting

  • CaRe Research

    Chubbuck, Idaho · Recruiting

  • DaVita Clinical Research

    Las Vegas, Nevada · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • OSU Wexner Medical Center

    Columbus, Ohio · Recruiting

  • Prolato Clinical Research Center

    Houston, Texas · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Novartis Investigative Site

    Ashdod, Israel · Recruiting

  • Novartis Investigative Site

    Hadera, Israel · Recruiting

  • Novartis Investigative Site

    Haifa, Israel · Recruiting

  • Novartis Investigative Site

    Nahariya, Israel · Recruiting

  • Novartis Investigative Site

    Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting

  • Novartis Investigative Site

    Kuala Lumpur, Selangor, Malaysia · Recruiting

  • Novartis Investigative Site

    Riyadh, Saudi Arabia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.